CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results
CHICAGO — An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation, study results showed. Researchers, who presented their findings at ASCO Annual Meeting, also noted that implementation of the AI-guided navigation workflow increased patient
A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer. Pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, has two approved indications for triple-negative breast cancer.
Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed. The findings, published in The American Journal of Cardiology, indicated that patients who harbored multiple risk factors had a significantly higher probability of sudden
Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.Metformin is a therapy used by patients with type 2 diabetes to treat high blood sugar by increasing the efficacy of insulin.